Department of Oncology, University Hospital of Udine, Udine, Italy.
Clin Breast Cancer. 2013 Jun;13(3):167-72. doi: 10.1016/j.clbc.2012.10.002. Epub 2012 Dec 5.
Thymidine phosphorylase (TP) expression has been found to be elevated in various solid tumors where it is likely involved in mechanisms that regulate cell proliferation, apoptosis, and angiogenesis. Based on these properties, it is tempting to hypothesize a potential prognostic role of TP, suggesting that a high TP expression could predict a poor outcome. On the other hand, TP expression has been studied for its role in predicting benefit from treatment with fluoropyrimidine-containing chemotherapy. Several studies have been conducted on breast cancer. The current evidence on the value of TP is not mature enough to allow its translation into clinical practice. However, several findings support the potentially predictive role of TP. In this light, TP appears to be a promising marker that can give helpful information to predict the benefit from capecitabine-based chemotherapy in patients with breast cancer.
胸苷磷酸化酶(TP)表达在各种实体瘤中升高,其可能参与调节细胞增殖、凋亡和血管生成的机制。基于这些特性,人们推测 TP 可能具有潜在的预后作用,表明高 TP 表达可能预示着不良预后。另一方面,TP 的表达已被研究用于预测氟嘧啶类化疗获益。已有多项关于乳腺癌的研究。目前关于 TP 价值的证据还不够成熟,无法将其转化为临床实践。然而,一些研究结果支持 TP 的潜在预测作用。从这个角度来看,TP 似乎是一种很有前途的标志物,可以提供有助于预测乳腺癌患者接受卡培他滨为基础化疗获益的信息。